U.S., Sept. 19 -- ClinicalTrials.gov registry received information related to the study (NCT07827586) titled 'Non-interventional Study of Subcutaneous Ocrelizumab in Persons With Relapsing-Remitting Multiple Sclerosis' on Sept. 15.
Brief Summary: The main purpose of the study is to assess patient-reported satisfaction with subcutaneous (s.c.) ocrelizumab administration in participants with relapsing-remitting multiple sclerosis (RRMS) who are treatment-naive, switching from intravenous (i.v.) ocrelizumab to s.c. ocrelizumab, or switching from a prior disease-modifying therapy (DMT) to s.c. ocrelizumab.
Study Start Date: Sept. 30
Study Type: OBSERVATIONAL
Condition:
Relapsing-Remitting Multiple Sclerosis
Intervention:
DRUG: Ocrelizuma...